Can A Transformed ANVISA Sustain Torrent's Brazilian Mojo?
Executive Summary
Price gains and a regulator that has turned more responsive appear to be among the key factors contributing to the improving sentiment in Brazil for India's Torrent even as the South American nation tackles intense political and economic turbulence. While Torrent reported a sharp decline in its earnings in the first quarter largely due to exceptional gains in the comparable previous period, its Brazilian business is looking up.
You may also be interested in...
Medical Device Regulations In Latin America And The Way Forward
Akhila Krishnan reviews the different regulatory requirements for medical devices in five Latin American countries and discusses how harmonization initiatives will make things easier for manufacturers in this guest column.
How India’s Torrent Is Building Resilience In Brazil
India’s Torrent Pharmaceuticals reported a strong set of numbers for the third quarter ended December 2015 despite turbulence in markets like Brazil, where it has done some sharp "belt tightening" but remains bullish over the long term.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.